All patients
age >= 60 yr age >= 65 yr corticosteroids: no corticosteroids: yes invasive ventilation non invasive oxygen subjects at risk
antiviral and associated therapy in COVID 19 all comers - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results NIH NIAID ACTT-1, 2020 0.73 [0.52; 1.03]
0.73 [0.52 ; 1.03 ] NIH NIAID ACTT-1, 2020 1 0% 1,062 NA not evaluable deathsdetailed results Lou (FAVIPIRAVIR), 2020 1.12 [0.02; 62.74]
NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
0.61 [0.35 ; 1.09 ] Lou (FAVIPIRAVIR), 2020, NIH NIAID ACTT-1, 2020, NOR-Solidarity (hydroxychloroquine), 2021 3 4% 1,193 moderate not evaluable deaths (time to event analysis only)detailed results NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
0.87 [0.19 ; 3.85 ] NIH NIAID ACTT-1, 2020, NOR-Solidarity (hydroxychloroquine), 2021 2 50% 1,174 moderate not evaluable clinical improvementdetailed results Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62]
NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
1.29 [1.12 ; 1.49 ] Lou (FAVIPIRAVIR), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,081 moderate not evaluable clinical improvement (14-day)detailed results Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62]
1.25 [0.21 ; 7.62 ] Lou (FAVIPIRAVIR), 2020 1 0% 19 NA not evaluable clinical improvement (28-day)detailed results NIH NIAID ACTT-1, 2020 1.35 [1.03; 1.76]
1.35 [1.03 ; 1.76 ] NIH NIAID ACTT-1, 2020 1 0% 1,062 NA not evaluable clinical improvement (time to event analysis only)detailed results NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
1.29 [1.12 ; 1.49 ] NIH NIAID ACTT-1, 2020 1 0% 1,062 NA not evaluable viral clearance detailed results Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75]
0.18 [0.01 ; 4.75 ] Lou (FAVIPIRAVIR), 2020 1 0% 19 NA not evaluable viral clearance by day 14detailed results Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75]
0.18 [0.01 ; 4.75 ] Lou (FAVIPIRAVIR), 2020 1 0% 19 NA not evaluable ICU admissiondetailed results Lou (FAVIPIRAVIR), 2020 5.43 [0.21; 139.89]
5.43 [0.21 ; 139.89 ] Lou (FAVIPIRAVIR), 2020 1 0% 19 NA not evaluable serious adverse eventsdetailed results NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96]
0.72 [0.54 ; 0.96 ] NIH NIAID ACTT-1, 2020 1 0% 1,063 NA not evaluable deep vein thrombosisdetailed results NIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81]
0.64 [0.23 ; 1.81 ] NIH NIAID ACTT-1, 2020 1 0% 1,063 NA not evaluable elevated liver enzymesdetailed results NIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18]
0.67 [0.38 ; 1.18 ] NIH NIAID ACTT-1, 2020 1 0% 1,063 NA not evaluable hyperbilirubinemiadetailed results NIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34]
0.84 [0.30 ; 2.34 ] NIH NIAID ACTT-1, 2020 1 0% 1,063 NA not evaluable pulmonary embolismdetailed results NIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80]
0.96 [0.19 ; 4.80 ] NIH NIAID ACTT-1, 2020 1 0% 1,063 NA not evaluable renal impairmentdetailed results NIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61]
1.02 [0.64 ; 1.61 ] NIH NIAID ACTT-1, 2020 1 0% 1,063 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2025-03-09 15:55 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 94
- treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814
- roots T: 290
